All points
4211 words
- Dr. David Agus leads the Ellison Medical Institute at the University of Southern California and is a professor of medicine at USC. He is a prominent oncologist whose work combines cancer treatment, laboratory research, drug development, and technology.
- Cancer can result from inherited genetics, behavior, or environmental exposures. Agus explains that cancer requires changes in DNA, which can either be inherited or develop during a person's lifetime.
- Several dozen inherited genes can substantially increase cancer risk when they contain harmful mutations. People carrying certain inherited genetic alterations may face dramatically higher risks than the general population.
- Cancer-causing DNA changes do not have to come from one's parents. Smoking, environmental exposures, and other behaviors can induce genetic changes that contribute to cancer development.
- Cancer treatment has advanced enormously since President Richard Nixon declared a war on cancer more than 50 years ago, but the disease has not been cured. Agus credits major scientific progress while emphasizing that substantial problems remain.
- Immunotherapy allows a patient's own immune system to attack cancer. Agus identifies the ability to harness immune responses against tumors as one of the major advances in modern oncology.
- Molecularly targeted treatments can attack specific genetic abnormalities in cancer cells. Sequencing a tumor's DNA can identify molecular alterations that may be targeted with drugs, sometimes allowing doctors to interfere with the biological signals driving the cancer.
- Agus says tumor DNA sequencing and related molecular testing are increasingly accessible through medical coverage, including Medicare. Such testing can help identify patients whose cancers may respond to specific targeted therapies.
- Full-body MRI examinations avoid the radiation exposure associated with certain other imaging methods. Agus acknowledges their potential usefulness but distinguishes their technical safety from the unresolved question of whether routinely scanning healthy people improves survival.
- Finding cancer on a scan does not automatically mean it has been detected early enough to improve the outcome. Agus notes that a tumor measuring just one centimeter may already contain hundreds of millions of cancer cells.
- Routine full-body scanning has not been demonstrated to produce major improvements in outcomes for most cancers. Agus argues that broader screening benefits must be established rather than assumed from the ability to detect abnormalities.
- Lung cancer screening is a notable example of imaging that can save lives through earlier detection. Agus advocates regular scans for smokers because detecting lung cancer before it becomes advanced can make curative treatment possible.
- Breast cancer screening is another established example of successful early detection. Mammography can identify tumors at earlier stages, when treatment outcomes are generally better.
- Cancer research receives far more attention and resources for treatment than for early diagnosis, according to Agus. He argues that improved imaging and blood tests capable of identifying cancer earlier deserve substantially greater investment.
- Cancer survival is commonly evaluated using five-year survival rates measured from diagnosis. The interviewer uses this measure to discuss differences in outcomes between cancers and stages of disease.
- Cancer staging describes how far the disease has spread, although exact definitions differ between cancer types. Agus describes stage one as localized disease, stages two and three as progressively more extensive spread, and stage four as cancer that has metastasized to distant parts of the body.
- Survival generally decreases as cancer advances through the stages. Agus emphasizes that greater disease spread is associated with worse outcomes, although the prognosis depends on the particular cancer.
- The interviewer cites an approximately 98% survival rate for breast cancer detected at stage one. He presents this as an example of why mammography and early identification are valuable, rather than as a figure independently established during the conversation.
- Agus supports considering PSA blood testing for prostate cancer detection. However, he recognizes the longstanding debate over whether routine testing leads to unnecessary investigations and treatment.
- Elevated PSA results can trigger unnecessary prostate biopsies, operations, and radiation treatments. Agus acknowledges these harms and argues that finding a cancer does not always justify immediately treating it.
- Some prostate, thyroid, and breast cancers grow slowly enough that aggressive treatment may provide little benefit. Agus identifies these as indolent cancers, where medical intervention can produce substantial side effects without improving outcomes.
- Active surveillance allows doctors to monitor selected cancers rather than treating them immediately. Agus argues that patients need better guidelines and explanations so that a cancer diagnosis does not automatically produce pressure for surgery or radiation.
- The word cancer itself can create fear that drives overtreatment. Agus believes doctors must better explain the difference between finding an abnormal cancerous growth and finding a disease that actually threatens the patient's life.
- Slow-growing prostate cancers are extremely common among older men. Agus suggests that biopsying large numbers of men over 60 would uncover many previously undetected tumors, most of which would never cause serious problems.
- The presence of prostate cancer does not mean it will ultimately cause a man's death. Agus rejects the assumption that all detected prostate tumors are dangerous, emphasizing the difference between harmless or slowly growing tumors and aggressive disease.
- Changes in PSA over time can be more informative than a single PSA measurement. Agus highlights the slope of the PSA curve as a tool for identifying cancers that may behave more aggressively.
- Prostate biopsies help distinguish dangerous tumors from cancers that can safely be monitored. Microscopic examination allows physicians to grade tumor aggressiveness and make better-informed treatment decisions.
- Patrick Walsh at Johns Hopkins pioneered nerve-sparing prostatectomy to reduce complications of prostate cancer surgery. Earlier operations frequently damaged nerves that were difficult to distinguish from surrounding prostate tissue.
- Damage to those nerves caused major problems with urinary continence and sexual function. Walsh's surgical innovation sought to preserve the nerves responsible for these functions while removing the diseased prostate.
- Walsh developed his understanding of the relevant nerve anatomy by studying deceased young children. Agus describes this anatomical research as a crucial step in identifying the nerves surgeons needed to protect.
- Robotic-assisted prostate surgery offers improved visualization through magnified imaging. Surgeons can operate through small incisions while viewing enlarged images of structures deep within the body.
- Inflating the abdomen during robotic-assisted surgery helps create operating space and reduce bleeding. Agus says these techniques can improve surgical precision, reduce side effects, and sometimes allow patients to return home the same day.
- Agus does not describe a dramatic overall rise in U.S. cancer incidence, but identifies an important shift toward younger patients. He distinguishes changes in the ages of people developing cancer from claims that cancer rates are rapidly increasing across the entire population.
- More people in their twenties, thirties, and forties are developing cancers previously associated more strongly with older adults. Agus specifically highlights colorectal and breast cancer as examples of this troubling pattern.
- The reasons for increasing cancer incidence among younger adults remain unknown. Agus says possible explanations have attracted attention, but there is insufficient evidence to identify a definitive cause.
- Environmental exposures, dietary changes, ultra-processed foods, microplastics, and changes in the microbiome are among the suspected contributors. Agus presents them as hypotheses rather than established explanations.
- Agus criticizes the United States for lacking sufficiently comprehensive data collection to investigate changes in cancer patterns. He argues that better information about patients and their exposures is necessary to identify causes of emerging trends.
- Cancers affecting younger patients may have different biological characteristics from those found in older patients. Agus believes these differences deserve greater research attention.
- Many conventional cancer treatment regimens were developed primarily around older patients. Agus argues that younger patients may benefit from approaches designed around their particular cancer biology rather than automatically applying treatments developed for older populations.
- The recommended starting age for routine colorectal cancer screening was lowered from 50 to 45. Agus considers this a response to changing disease patterns and suggests that the screening age may eventually need to fall further.
- People with a family history of cancer may need screening earlier than the general population. Agus emphasizes that inherited risk should influence both the timing and type of preventive care.
- Healthy eating, physical exercise, and annual medical examinations form the foundation of Agus's cancer prevention advice. He sees preventive care as a continuing process rather than something patients should begin only after developing symptoms.
- Regular blood testing can help doctors monitor health and identify potentially important risk factors. Agus recommends establishing an appropriate testing schedule with a physician instead of relying exclusively on occasional medical examinations.
- Certain medications, including aspirin and statins, may reduce cancer risks in selected patients. Agus recommends discussing these drugs with a doctor because the potential benefits depend on individual circumstances.
- Knowing the medical history of relatives is an important part of cancer prevention. Agus advises learning what diseases affected parents, grandparents, aunts, uncles, and other relatives because inherited risk can run through families.
- Past generations often concealed cancer diagnoses because the disease carried social stigma. Agus says cancer was sometimes treated as a personal weakness, making it difficult for later generations to reconstruct accurate family medical histories.
- Genetic sequencing can now identify inherited cancer-risk mutations quickly and comparatively cheaply. Agus says a person's genome can be sequenced overnight and estimates that testing relevant inherited cancer-risk genes can cost approximately $100.
- Identifying inherited mutations can support individually targeted prevention. Rather than giving everyone the same screening and preventive measures, Agus favors adjusting care to a person's specific inherited risks.
- The Ellison Medical Institute employs approximately 250 people. Agus oversees the institute while continuing his responsibilities in research, teaching, and direct patient care.
- The institute operates as a technology-focused biomedical research organization that develops drugs. Its activities include applying artificial intelligence to the design of molecules intended to interfere with cancer-related biological processes.
- Artificial intelligence can help researchers determine the structures of biological targets and design molecules capable of interacting with them. Agus says this can compress work that previously took years into a matter of months.
- The institute has designed a potential prostate cancer drug targeting part of the disease's signaling pathway. At the time of the interview, Agus expected the molecule to advance into clinical testing the following year.
- The institute has also designed a breast cancer molecule using artificial intelligence. Agus describes both projects as part of a growing pipeline of potential cancer treatments enabled by computational drug design.
- Agus believes artificial intelligence is materially accelerating drug discovery, not merely assisting administrative tasks. He identifies molecular design as an area in which the technology is already changing research timelines.
- The interviewer, aged 75, asks how to protect his memory and avoid Alzheimer's disease or other forms of dementia. His question reflects concern about both physical decline and loss of mental ability during aging.
- Agus cites a large European study associating each additional year before retirement with a 3% reduction in Alzheimer's incidence. He uses the finding to argue for continued mental activity, although the conversation does not establish that delaying retirement itself causes the reduction.
- Keeping the brain actively engaged is central to Agus's advice for cognitive aging. He encourages activities that create intellectual challenges and discomfort rather than allowing mental routines to become progressively less demanding.
- Agus has treated prominent patients, including Steve Jobs and Jack Kemp. He says famous patients do not fit a single personality pattern and can approach medical decisions very differently.
- Former American politician Jack Kemp invited Agus to his home shortly after becoming his patient. Agus initially expected a private discussion about Kemp's medical condition.
- Kemp instead assembled his family around a large dinner table and had members of his church serve dinner. He wanted Agus to understand his family, community, beliefs, and personal values before making major medical decisions.
- Kemp explicitly entrusted medical decision-making to Agus while asking him to understand what mattered in his life. Agus remembers the experience as an unusually meaningful demonstration of trust between a patient and physician.
- Agus considers the trust patients place in their doctors a privilege, regardless of their wealth or public prominence. He emphasizes the responsibility involved when patients entrust their health and futures to medical professionals.
- Agus was born in Baltimore, Maryland. His father attended Johns Hopkins as an undergraduate and completed medical school at the University of Maryland.
- Agus's father was drafted into the Air Force, leading the family to live in San Antonio, Texas. The family later moved to Philadelphia, where his father worked as a professor.
- Agus attended St. Mary's Hall in San Antonio and was among the first two boys admitted to the school. He remembers being one of only two male students in first grade during the school's transition to coeducation.
- Agus completed his undergraduate education at Princeton University and attended medical school at the University of Pennsylvania. He subsequently completed his internship and residency at Johns Hopkins.
- His advanced medical training included a fellowship at Memorial Sloan Kettering Cancer Center and several years at the National Institutes of Health. This sequence gave him experience in clinical medicine and biomedical research before his later leadership roles.
- Agus developed a strong interest in scientific research during childhood. Growing up in the years following Sputnik, he participated in a competition that selected four children for visits to laboratories around the United States.
- The laboratory visits allowed Agus to experiment directly with scientific work and helped establish his interest in research. He eventually realized he wanted to apply laboratory discoveries to patients rather than remain exclusively in the laboratory.
- Oncology attracted Agus because experimental discoveries could be translated relatively quickly into clinical treatment. He also found that cancer patients facing serious illnesses were sometimes willing to accept risks associated with experimental approaches.
- Agus combines laboratory research and clinical medicine rather than choosing one career path. He views the ability to investigate biological problems while treating the people affected by them as a defining feature of his professional life.
- Agus manages his substantial professional workload by deliberately declining commitments. Despite running the institute, teaching, and treating patients, he says he prioritizes being home for dinner every day.
- He regularly refuses social invitations and avoids unnecessary evening activities. Having responsibility for patients also provides a practical reason to decline engagements that would interfere with his preferred schedule.
- Agus maintains consistent times for waking, eating, and sleeping. He considers regular daily routines important for physical health, metabolism, and productivity.
- Agus discourages irregular snacking because he believes it disrupts the body's metabolic and hormonal rhythms. He argues that repeatedly eating between scheduled meals can alter insulin and stress-hormone responses, affect productivity, and contribute to weight gain.
- Agus has two children, one of whom pursued medical school. He says his youngest child's eventual interest in medicine was not the result of parental pressure.
- His youngest son attended MIT and was initially focused on programming, artificial intelligence, and data. He was strongly oriented toward technology rather than a medical career.
- Working on COVID-19 data analysis and software supporting clinical trials changed the younger son's professional interests. Agus says the experience helped his son recognize that he wanted to use his abilities to help people and work on problems with direct human consequences.
- Agus strongly supports statins for appropriate patients because of their ability to lower LDL cholesterol. He identifies lower LDL as beneficial for cardiovascular risk and also associates statin use with possible reductions in cancer risk.
- Family histories of heart disease or cancer can influence Agus's recommendations about cholesterol management. He favors helping higher-risk individuals achieve LDL levels appropriate to their circumstances rather than treating every person identically.
- Agus does not consider moderate red-meat consumption inherently incompatible with good health. He cites a large European study that found no health detriment associated with approximately three servings per week.
- Agus also refers to studies suggesting possible benefits from grass-fed beef. His central dietary recommendation is moderation rather than eliminating all red meat.
- Processed meat receives a substantially stronger warning than unprocessed red meat. Agus advises avoiding habitual consumption of processed meats, especially over long periods.
- Agus cites approximately a 20% increase in colon cancer risk associated with prolonged daily processed-meat consumption. He illustrates the concern with the example of eating a hot dog every day for 20 years.
- The interviewer says he avoids red meat but questions whether doing so will actually extend his life. Agus's response suggests that overall dietary patterns and the quantity and processing of meat matter more than a simple rule against all red meat.
- Alcohol consumption is associated with increased cancer risk, particularly breast cancer in women. Agus describes the association discussed in the interview as relatively small, without claiming that alcohol is harmless.
- The interviewer also abstains from alcohol and asks whether that will help him live longer. Agus does not promise a longevity benefit from abstinence, instead discussing the complexity of interpreting associations between individual exposures and disease.
- Agus discusses acrylamide, a chemical that can form during high-temperature cooking and browning. He identifies browned toast and roasted coffee beans as examples of exposure and describes acrylamide as having carcinogenic properties.
- Agus considers acrylamide exposure from ordinary foods a comparatively minor contributor to cancer risk. He argues that publicity surrounding such exposures can make their significance appear greater than he believes the evidence warrants.
- Agus recommends establishing an individual's health baseline before designing a longevity plan. His approach begins with understanding existing risks, medical conditions, cardiovascular health, and relevant test results.
- Cardiovascular imaging may be worth considering as part of that assessment. Agus includes heart imaging among the potential investigations to discuss when developing a preventive health strategy.
- Staying current with recommended vaccinations is a critical part of Agus's health advice. He also emphasizes maintaining appropriate blood-test values and checking for inherited risks when family history suggests them.
- The interviewer proposes a longevity routine involving exercise, moderate consumption of meat and alcohol, and potentially aspirin and statins. Agus supplements this with individual risk assessment, cardiovascular evaluation, vaccinations, blood testing, and genetic testing where appropriate.
- Agus cites research identifying ages 43 and 60 as periods of particularly significant biological change. He says the study examined biological aging and found major shifts in health around those two ages.
- Agus observes that health changes in middle age and later adulthood can make people more conscious of mortality. He associates the ages highlighted by the study with periods when patients begin to recognize their vulnerability to serious illness.
- Agus routinely recommends that patients with cancer put their personal and financial affairs in order, even when he expects them to survive. He distinguishes practical preparation from a prediction that death is imminent.
- He sometimes tells patients that their cancer is controllable and unlikely to kill them, then advises them to make appropriate arrangements for the future. His position is that preparing for an unexpected outcome remains sensible even when the prognosis is favorable.
- Agus favors the principle of hoping for the best while planning for the worst. He considers wills, estate arrangements, and other preparations part of responsible planning rather than an admission of defeat.
- Failure to prepare for death can produce serious disputes among surviving family members. Agus says he has seen families become involved in painful conflicts because arrangements were not made in advance.
- Agus rejects the idea that advising someone to get their affairs in order is inherently alarming or inappropriate. He believes the advice should be normalized rather than interpreted as a signal that a doctor has abandoned hope.
- Agus believes people will eventually be able to reach 100 with physical and cognitive abilities more comparable to those of people in their seventies or eighties. He expresses strong confidence that longer life can be accompanied by substantially better health.
- His longevity goal is to extend healthy, independent years rather than simply prolong life. He argues that living to 100 should not necessarily mean spending the final decades with serious physical limitations or cognitive impairment.
- Agus says the early 1960s marked the end of an era when old age could be recorded as a cause of death on U.S. death certificates. He contrasts that with the modern practice of specifying diseases such as heart disease, Alzheimer's, or cancer.
- Agus would like medicine to make it possible for more people to die at advanced ages without prolonged suffering from major diseases. His vision is of aging in which disease and disability are delayed or prevented for much longer.
- People frequently ask Agus for informal medical advice at social gatherings. He acknowledges that these unsolicited consultations are common and that his wife finds them irritating.
- Agus nevertheless welcomes opportunities to provide brief medical guidance. He considers the small amount of time required to answer a question worthwhile when the information might materially improve another person's health.
- Agus describes an unequal relationship between the effort required of the doctor and the potential benefit to the person receiving advice. Something that takes him only seconds to explain may have substantial value for someone who lacks medical knowledge.
- Agus strongly criticizes commercial stem-cell clinics and anti-aging businesses promising rejuvenation without credible clinical evidence. He specifically mentions clinics, nutritional centers, and retailers promoting supplements or regenerative interventions as fountains of youth.
- He describes unsupported commercial anti-aging promises as fraudulent. His objection is that persuasive marketing and scientific terminology are being used to sell treatments whose claimed benefits have not been demonstrated.
- Scientific interest in stem cells does not establish that every product marketed as a stem-cell treatment is effective. Agus warns that consumers may incorrectly assume that a commercially advertised treatment works simply because legitimate researchers are studying the same general technology.
- Agus believes stem-cell and regenerative technologies have genuine long-term potential despite their premature commercial promotion. He separates credible experimental research from services already being sold to consumers.
- Clinical trials are investigating regenerative approaches after hip fractures in elderly patients. Agus describes research intended to reactivate cellular repair processes following the surgical treatment of these injuries.
- Other experimental regenerative treatments are being investigated for the heart, eyes, and hair. Agus identifies these as areas in which stimulating the body's own repair capacity could eventually lead to medical advances.
- The larger ambition of regenerative medicine is to reactivate biological repair mechanisms that become less effective with age. Agus believes this could eventually help restore function and preserve quality of life much later into adulthood.
- Agus stresses that promising regenerative technologies remain at an early stage. He expects future progress but says the underlying science must be improved and tested before such treatments can deliver the results commercial providers currently advertise.
- Agus particularly enjoys caring for patients with advanced cancers who have exhausted conventional treatment options. These cases allow him to investigate unusual possibilities and search for treatments that might help when established methods have failed.
- His approach to difficult cancers combines patient-specific information, research evidence, and unconventional therapeutic reasoning. He describes reviewing available data to identify approaches that might work for patients with few remaining options.
- Cancer cells can evolve in response to treatment over periods of weeks or months. Agus says administering a drug allows him to observe changes in tumor biology as cancer responds, adapts, or develops resistance.
- Studying how cancer changes under drug pressure helps Agus understand its underlying biology. He treats the response to therapy as both a clinical event and a source of scientific information that may improve future treatments.
- Agus considers physicians who combine active laboratory research with direct patient treatment increasingly uncommon. He values the opportunity to move continuously between investigating disease mechanisms and observing them in actual patients.
- Agus performs autopsies on patients who die under his care to understand what happened. He uses the findings to identify what he recognized correctly, what he missed, and where his medical judgments may have been wrong.
- Learning from unsuccessful treatments is an explicit part of Agus's medical practice. He regards examining treatment failures and patient outcomes as essential to becoming a better physician and researcher.
- Agus identifies helping people and solving difficult medical problems as the greatest rewards of his profession. He values both directly assisting individual patients and developing knowledge or treatments that may benefit people around the world.
- Agus believes admission to medical school has become substantially more difficult since he was a student. He jokes that he might not be accepted under today's admissions and examination requirements.
- Despite the appeal of modern technology careers, Agus says he would probably choose medicine again rather than Silicon Valley. His experience with research, patient care, and medical innovation has reinforced his commitment to the profession.
- Agus remains deeply enthusiastic about his work after decades in medicine. He describes his career as an opportunity he continues to appreciate every day, particularly because it allows him to connect scientific discovery with meaningful improvements in people's lives.